Merus Labs Names Barry Fishman as Senior Advisor

Appointment Enhances Firm's Healthcare Industry Contacts Adds Strategic and Operational Expertise

Toronto, April 23, 2014 - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI), a Canadian publicly traded specialty pharmaceutical company, announced today that Barry Fishman has joined as Senior Advisor. In this part-time capacity, Barry will assist Merus Labs in identifying investment opportunities, facilitating key industry introductions, and advising the firm on strategic and operational issues. Barry has over 25 years of experience in the pharmaceutical industry and is the former President & CEO of Teva Canada. During his tenure, operating profit increased by 75% and market share grew by 70%. Barry is also the past Chair of the Canadian Generic Manufacturers Association. Barry started his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing.

"We are extremely excited to have Barry join the Merus team," said Elie Farah, CEO of Merus Labs "Barry is an accomplished leader in the industry and is highly regarded by his peers. We will benefit greatly from his extensive pharmaceutical experience, expertise and relationships." Mr. Fishman commented, "I am very pleased to be a part of the Merus team. I am impressed with the firm's core values, culture, and future potential. I look forward to working closely with Merus and assisting their efforts to acquire income generating assets that help patients and build shareholder value."

"Barry brings tremendous experience nationally and internationally across a number of segments in the pharmaceutical market. I've personally known Barry for many years and am thrilled that we have access to his insights and expertise," commented Mr. Michael Cloutier, Chairman of the Board of Merus.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities

Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, Merus' ability to complete any financing under its short form prospectus or otherwise, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

For further information please contact:

Merus Labs International Inc.

Tel: (416) 593-3725

Or contact our investor relations department at: info@meruslabs.com